Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | FNTA | P49354 | 1/20 | 0.34 |
| ▸ | FNTB | P49356 | 1/20 | 0.34 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20607875 | 0.92 | KDM4E (0.35) | ALDH1A1KDM4EHPGDHSD17B10TRPV4 | |
| SCHEMBL500818 | 0.85 | SLC6A4 (0.34) | ALDH1A1KDM4EHPGDHSD17B10TRPV4 | |
| SCHEMBL4774237 | 0.84 | ALDH1A1 (0.37) | ALDH1A1KDM4EHPGDHSD17B10CYP2A6 | |
| SCHEMBL5534795 | 0.82 | APP (0.35) | MEN1TTRALBKMT2A | |
| SCHEMBL2934457 | 0.82 | CYP2A6 (0.47) | ALDH1A1TRPV4CYP2A6MEN1TTR | |
| SCHEMBL1715050 | 0.81 | IDO1 (0.48) | SLC6A4KCNH2SLC6A3MEN1TTR | |
| SCHEMBL4773225 | 0.79 | MEN1 (0.43) | ALDH1A1HSD17B10CYP2A6MEN1TTR | |
| SCHEMBL1232549 | 0.78 | ALDH1A1 (0.38) | ALDH1A1KDM4EHSD17B10KMT2A | |
| SCHEMBL31314271 | 0.77 | TRPV4 (0.46) | TRPV4CYP2A6KCNH2HTR2AMEN1 | |
| SCHEMBL4767252 | 0.76 | TSHR (0.42) | HSD17B10CYP2A6TLR7SLC6A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023224963-A1 | DUAL-ACTING ANGIOTENSIN AND ENDOTHELIN RECEPTOR ANTAGONISTS | ARIA PHARMACEUTICALS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023224963-A1 | DUAL-ACTING ANGIOTENSIN AND ENDOTHELIN RECEPTOR ANTAGONISTS | ARIA PHARMACEUTICALS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023066348-A1 | DUAL ANTAGONIST AND USE THEREOF | 年衍药业（上海）有限公司 | 2023-04-27 | — | — | WO | disclosed |
| EP-3708163-A1 | USE OF SPARSENTAN FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | Ligand Pharmaceuticals, Inc. (US) | 2020-09-16 | — | — | EP | disclosed |
| EP-3222277-B1 | A BIPHENYLSULFONAMIDE ENDOTHELIN AND ANGIOTENSIN II RECEPTOR ANTAGONIST TO TREAT GLOMERULOSCLEROSIS AND IGA-INDUCED NEPHROPATHY | LIGAND PHARM INC (US) | 2020-02-26 | — | — | EP | disclosed |
| US-20180344705-A1 | METHOD FOR TREATING CHRONIC INFLAMMATORY DISEASES | LIGAND PHARMACEUTICALS INC. | 2018-12-06 | — | — | US | disclosed |
| US-9993461-B2 | Method for treating disorders associated with glomerular function | LIGAND PHARMACEUTICALS INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9993461-B2 | Method for treating disorders associated with glomerular function | LIGAND PHARMACEUTICALS INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170354646-A1 | METHOD FOR TREATING DISORDERS ASSOCIATED WITH GLOMERULAR FUNCTION | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2017-12-14 | — | — | US | disclosed |
| US-20170354646-A1 | METHOD FOR TREATING DISORDERS ASSOCIATED WITH GLOMERULAR FUNCTION | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2017-12-14 | — | — | US | disclosed |
| EP-1741713-A2 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | Bristol-Myers Squibb Company (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1237888-B1 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2006-09-13 | — | — | EP | disclosed |
| US-6852745-B2 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-08 | — | — | US | disclosed |
| US-6835741-B2 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-28 | — | — | US | disclosed |
| US-20040127515-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040106833-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2004-06-03 | — | — | US | disclosed |
| US-6638937-B2 | As antihypertensive agents; for therapy of disorders related to renal, glomerular and mesangial cell function; therapy of endotoxemia or endotoxin shock as well as hemorrhagic shock; useful in alleviation of pain associated cancer | BRISTOL-MYERS SQUIBB CO. | 2003-10-28 | — | — | US | disclosed |
| US-20020143024-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2002-10-03 | — | — | US | disclosed |
| EP-1237888-A2 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001044239-A2 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB CO. (US) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127515-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | ALDH1A1 1854/4885KDM4E 1602/4885HPGD 2415/4885 |
| US-20180344705-A1 | METHOD FOR TREATING CHRONIC INFLAMMATORY DISEASES | AGTR2, AGTR1, EDNRA | ALDH1A1 1107/4885KDM4E 3429/4885HPGD 715/4885 |
| US-20020143024-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | ALDH1A1 1854/4885KDM4E 1602/4885HPGD 2415/4885 |
| US-20040106833-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | ALDH1A1 1854/4885KDM4E 1602/4885HPGD 2415/4885 |
| US-20170354646-A1 | METHOD FOR TREATING DISORDERS ASSOCIATED WITH GLOMERULAR FUNCTION | REN, AGTR2, AGTR1 | ALDH1A1 1720/4885KDM4E 3882/4885HPGD 1181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.